<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01186913</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT RDCRN PIDTC-6901</org_study_id>
    <nct_id>NCT01186913</nct_id>
  </id_info>
  <brief_title>Natural History Study of SCID Disorders</brief_title>
  <official_title>A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with Primary Immune Deficiency (PID) may develop severe, life-threatening infections
      as a result of inherited defects in the genes that normally instruct blood-forming cells to
      develop and to fight infections. PID diseases include Severe Combined Immune Deficiency
      (SCID), leaky SCID, Omenn syndrome (OS), and Reticular Dysgenesis (RD).  PIDs may be treated
      by transplantation of bone marrow stem cells from a healthy person or, in some cases, by
      enzyme replacement or by gene therapy.  Patients with SCID were among the first to receive
      bone marrow stem cell (also called hematopoietic cells) transplantation (HCT) more than 40
      years ago, and HCT is the standard treatment today for this group of diseases.   Since PID
      diseases are rare, there are not enough patients at any single center to determine the full
      range of causes, natural history, or best methods of treatment.  For this research study
      many PID centers across North America have organized into the Primary Immune Deficiency
      Treatment Consortium (PIDTC) to pool their experience and study PIDs together. The overall
      goal of this study is the prospective evaluation of children with SCID and related disorders
      who are treated under a variety of protocols at participating institutions.  The study aims
      to identify variables contributing to the best outcomes for HCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model:  Cohort, Time Perspective:  Prospective</study_design>
  <primary_outcome>
    <measure>Overall survival following HCT</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Full T cell reconstitution</measure>
    <time_frame>6 months post HCT</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full T cell reconstitution</measure>
    <time_frame>12 months post HCT</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full T cell reconstitution</measure>
    <time_frame>24 months post HCT</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full B cell reconstitution</measure>
    <time_frame>12 months post HCT</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full B cell reconstitution</measure>
    <time_frame>24 months post HCT</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth and Nutrition</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft versus Host Disease</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of autoimmunity requiring treatment</measure>
    <time_frame>Throughout the study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopment/Neurocognition</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other complications of HCT needing treatment</measure>
    <time_frame>Throughout the study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">265</enrollment>
  <condition>SCID</condition>
  <condition>Leaky SCID</condition>
  <condition>Omenn Syndrome</condition>
  <condition>Reticular Dysgenesis</condition>
  <condition>ADA Deficiency</condition>
  <condition>XSCID</condition>
  <arm_group>
    <arm_group_label>Stratum A</arm_group_label>
    <description>Patients with classic SCID after allogeneic hematopoietic stem cell transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum B</arm_group_label>
    <description>Patients with leaky SCID, Omenn syndrome, or Reticular Dysgenesis after allogeneic hematopoietic stem cell transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum C</arm_group_label>
    <description>Patients with ADA Deficiency or XSCID who are treated with PEG-ADA (patients with ADA Deficiency) or patients who are treated with gene therapy (ADA Deficiency or XSCID)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be selected from 14 participating centers and additional Pediatric Blood and
        Marrow Transplant Consortium centers caring for SCID patients in North America
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stratum A, Classic SCID Patients who meet the following inclusion criteria and the
             intention is to treat with allogeneic hematopoietic cell transplant (HCT) are
             eligible for enrollment into Stratum A - Absence or very low number (&lt; 300 / ul) of T
             cells, AND no or very low (&lt;10% of lower limit of normal) T cell function (as
             measured by response to phytohemagglutinin OR T cells of maternal origin present, but
             with &lt;10% of lower limit of normal T cell function (as measured by response to PHA)

        Stratum B, Leaky SCID, Omenn Syndrome, Reticular Dysgenesis Patients who meet the
        following criteria and the intention is to treat with HCT are eligible for enrollment into
        Stratum B-

        Leaky SCID:

          -  &lt;1000 / ul T cell number at &lt; age 2 years; &lt; 800 / ul T cell number at age 2 through
             &lt; 4 years; &lt; 600 / ul at &gt; 4 years; and maternal lymphocytes not detected, AND either
             one or both of the following with rule-out of MHC Class I or II non-expression by
             flow cytometry (or histology):

               1. ≥ 10% and ≤ 30% of lower limit of normal T cell function (as measured by
                  response to PHA), b) Absent proliferative responses to candida and tetanus
                  toxoid antigens (post vaccination or  exposure), with expression of HLA by
                  flow/serology

                  Omenn Syndrome:

          -  Generalized skin rash

          -  Maternal lymphocytes not detected

          -  Absent or low (&lt; 30% lower limit of normal) T cell proliferation to antigens

          -  &gt; 80% of CD4 T cells are CD45RO+ (&lt; 2 years of age)

        Reticular Dysgenesis:

          -  &lt; 300 / ul T cell number

          -  None or &lt; 10% lower limit of normal PHA proliferation

          -  Sensori-neural deafness

          -  Severe neutropenia (&lt; 200 / uL and unresponsive to G-CSF) and deficiency of marrow
             granulopoiesis unless there is known adenylate kinase 2 (AK2) pathogenic mutation(s)
             identified

        Stratum C, SCID with Non-HCT Treatments Patients who meet the following criteria and the
        intention is to treat with PEG-ADA or gene transfer with autologous modified cells are
        eligible for enrollment into Stratum C:

          -  ADA Deficient SCID with intention to treat with PEG-ADA

          -  ADA Deficient SCID with intention to treat with gene transfer

          -  X-linked SCID with intention to treat with gene transfer

        Exclusion Criteria:

          -  Patients who meet any one or more of the following exclusion criteria are
             disqualified from enrollment in Strata A, B, or C of the study:

          -  Presence of an HIV infection (by PCR) or other cause of secondary immunodeficiency.

          -  Presence of DiGeorge syndrome

          -  Most patients with other PIDs such as nucleoside phosphorylase deficiency, ZAP70
             deficiency, CD40 ligand deficiency, NEMO deficiency, XLP, cartilage hair hypoplasia
             or ataxia telangiectasia will not meet the inclusion criteria for Stratum A, B, or C
             above. However, a patient with one of the above may meet the inclusion criteria for
             Stratum B and if so will be included.

          -  MHC Class I and MHC Class II antigen deficiency are specifically excluded.

          -  Metabolic conditions that imitate SCID or related disorders such as folate
             transporter deficiency, severe zinc deficiency, transcobalamin deficiency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Buckley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Morton J. Cowan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrick Goldman, MD</last_name>
      <phone>205-939-5855</phone>
      <email>fgoldman@peds.uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renna Killen, RN</last_name>
      <phone>323-361-2217</phone>
      <email>rkillen@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Neena Kapoor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Moore, MD</last_name>
      <phone>310-825-6708</phone>
      <email>TBMoore@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Theodore Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-1278</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Dunn</last_name>
      <phone>415-476-4860</phone>
      <email>DunnE@peds.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Morton Cowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rajni Agarwal-Hashmi, MD</last_name>
      <phone>650-723-5535</phone>
      <email>rajnia@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Rajni Agarwal-Hashmi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralph Quinones, MD</last_name>
      <phone>720-777-6511</phone>
      <email>RQuinones@tchden.org</email>
    </contact>
    <investigator>
      <last_name>Ralph Quinones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Loechelt, MD</last_name>
      <phone>202-476-2800</phone>
      <email>BLoechel@cnmc.org</email>
    </contact>
    <investigator>
      <last_name>Brett Loechelt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Haight, MD</last_name>
      <phone>404-785-1272</phone>
      <email>Ann.haight@choa.org</email>
    </contact>
    <investigator>
      <last_name>Ann Haight, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Marshall</last_name>
      <phone>773-880-3459</phone>
      <email>memarshall@childrensmemorial.org</email>
    </contact>
    <investigator>
      <last_name>Morris Kletzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital/Louisiana State University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lolie Yu, MD</last_name>
      <phone>504-896-9740</phone>
      <email>lyu@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Lolie Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIH Clinical Center Genetic Immunotherapy Section</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Kang, MD</last_name>
      <phone>301-402-7567</phone>
      <email>ekang@niaid.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Braunstein, PNP</last_name>
      <phone>617-355-2457</phone>
      <email>jennifer.braunstein@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Sung-Yun Pai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Connelly, MD</last_name>
      <phone>737-936-4000</phone>
      <email>jaconnel@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>James Connelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Smith, MD</last_name>
      <phone>612-626-2778</phone>
      <email>smith719@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Angie Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Sanders, RN</last_name>
      <phone>314-268-2700</phone>
      <phone_ext>3513</phone_ext>
      <email>Wendy_Sanders@ssmhc.com</email>
    </contact>
    <investigator>
      <last_name>Alan Knutsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfred Gillio, MD</last_name>
      <phone>201-996-5645</phone>
      <email>agillio@humed.com</email>
    </contact>
    <investigator>
      <last_name>Alfred Gillio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Steven and Alexandra Cohen Children's Hospital of New York (previously Schneider Children's Hospital)</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Indira Sahdev, MD</last_name>
      <phone>718-470-3611</phone>
      <email>ISahdev@nshs.edu</email>
    </contact>
    <investigator>
      <last_name>Indira Sahdev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Doorish</last_name>
      <phone>646-888-5718</phone>
      <email>doorishc@mskc.org</email>
    </contact>
    <investigator>
      <last_name>Richard J O'Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Buckley, MD</last_name>
      <phone>919-684-2922</phone>
      <email>buck1003@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Buckley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Poston, BS</last_name>
      <phone>513-636-8815</phone>
      <email>angela.poston@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Lisa Filipovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evan Shereck, MD</last_name>
      <phone>503-494-0829</phone>
      <email>Shereck@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Evan Shereck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Sullivan, MD, PhD</last_name>
      <phone>215-590-1697</phone>
      <email>sullivak@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Sullivan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center/Children's of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Aquino, MD</last_name>
      <phone>214-648-8800</phone>
      <email>victor.aquino@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Aquino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chivon McMullen-Jackson, RN, BSN</last_name>
      <phone>832-824-1339</phone>
      <email>cdmcmull@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>William Shearer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas/Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ka Wah Chan, MD</last_name>
      <phone>(210) 575-7268</phone>
      <email>Kawah.Chan@MHShealth.com</email>
    </contact>
    <investigator>
      <last_name>Ka Wah Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pulsipher, MD</last_name>
      <phone>801-662-4830</phone>
      <email>michael.pulsipher@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Pulsipher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauri M Burroughs, MD</last_name>
      <phone>206-667-2396</phone>
      <email>lburroug@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Hans Ochs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-4874</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John M. Routes, MD</last_name>
      <phone>414-456-4802</phone>
      <email>jroutes@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>James Casper, MD</last_name>
      <phone>(414) 456-4170</phone>
      <email>jcasper@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John M. Routes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Casper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Davis, MD</last_name>
      <phone>(604) 875-3577</phone>
      <email>jdavis@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoff Cuvelier, MD</last_name>
      <phone>(204) 787-8689</phone>
      <email>geoff.cuvelier@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Geoff Cuvelier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU St. Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elie Haddad, MD</last_name>
      <phone>(514) 345-4931</phone>
      <phone_ext>6217</phone_ext>
      <email>elie.haddad@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Elie Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu</url>
  </link>
  <verification_date>October 2011</verification_date>
  <lastchanged_date>October 3, 2011</lastchanged_date>
  <firstreceived_date>August 20, 2010</firstreceived_date>
  <responsible_party>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>Agammaglobulinemia</mesh_term>
    <mesh_term>Leukopenia</mesh_term>
  </condition_browse>
</clinical_study>
